Silver Book Fact

Cancer patients in the U.S. experience greater survival gains than those in European countries, and the value of additional gains exceeds the additional cost of care in the U.S.

Philipson T, Eber M, Lakdawalla D, Corral M, et al. An Analysis of Whether Higher Health Care Spending is Worth it in the Case of Cancer. Health Affairs. 2012; 31(4): 667-75. http://content.healthaffairs.org/content/31/4/667.abstract

Reference

Title
An Analysis of Whether Higher Health Care Spending is Worth it in the Case of Cancer
Publication
Health Affairs
Publication Date
2012
Authors
Philipson T, Eber M, Lakdawalla D, Corral M, et al.
Volume & Issue
Volume 31, Issue 4
Pages
667-75
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.  
  • Widespread use of telomerase inhibitors could result in a 50% cure rate and a 25% prolongation of life for 50% of eligible patients with solid tumors.  
  • Estimated Number of Cancer Survivors in the United States From 1975 to 2012  
  • Following the current path, the colon cancer incidence rate will increase by 31.8% between 2003 and 2023 (447,000 people). If an alternative path is taken, there will be 17.7% (79,000…  
  • According to the Pharmaceutical Research and Manufacturers of America, researchers are currently working on 646 medicines for cancer. All are either in clinical trials or under FDA review. …